Literature DB >> 18534832

Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols.

Rania O Salama1, Daniela Traini, Hak-Kim Chan, Paul M Young.   

Abstract

Three in vitro methodologies were evaluated as models for the analysis of drug release from controlled release (CR) microparticulates for inhalation. USP Apparatus 2 (dissolution model), USP Apparatus 4 (flow through model) and a modified Franz cell (diffusion model), were investigated using identical sink volumes and temperatures (1000 ml and 37 degrees C). Microparticulates containing DSCG and different percentages of PVA (0%, 30%, 50%, 70% and 90%) were used as model CR formulations. Evaluation of the release profiles of DSCG from the modified PVA formulations, suggested that all data fitted a Weibull distribution model with R2 > or =0.942. Statistical analysis of the t(d) (time for 63.2% drug release) indicated that all methodologies could distinguish between microparticles that did or did not contain PVA (Students t-test, p<0.05). However, only the diffusion model could differentiate between samples containing different PVA percentages. Similar results were observed when analysing the data using similarity and difference factors. Furthermore, analysis of the release kinetic profiles for all samples suggested the data fitted the Higuchi diffusion model (R2 > or =0.862 for the diffusion methodology data set). Due to the relatively low water content in the respiratory tract and the lack of differentiation between formulations for USP Apparatus 2 and 4, it is concluded that the diffusion model is more applicable for the evaluation of CR inhalation medicines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18534832     DOI: 10.1016/j.ejpb.2008.04.009

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  22 in total

1.  Dissolution techniques for in vitro testing of dry powders for inhalation.

Authors:  Sabine May; Birte Jensen; Markus Wolkenhauer; Marc Schneider; Claus Michael Lehr
Journal:  Pharm Res       Date:  2012-04-20       Impact factor: 4.200

2.  Understanding the Impacts of Surface Compositions on the In-Vitro Dissolution and Aerosolization of Co-Spray-Dried Composite Powder Formulations for Inhalation.

Authors:  Sharad Mangal; Rongkun Xu; Heejun Park; Dmitry Zemlyanov; Nivedita Shetty; Yu-Wei Lin; David Morton; Hak-Kim Chan; Jian Li; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-11-07       Impact factor: 4.200

3.  Development of an in vivo ovine dry powder inhalation model for the evaluation of conventional and controlled release microparticles.

Authors:  Rania O Salama; Leigh Ladd; Hak-Kim Chan; Daniela Traini; Paul M Young
Journal:  AAPS J       Date:  2009-07-01       Impact factor: 4.009

4.  Solid lipid budesonide microparticles for controlled release inhalation therapy.

Authors:  Matteo Mezzena; Santo Scalia; Paul M Young; Daniela Traini
Journal:  AAPS J       Date:  2009-11-12       Impact factor: 4.009

Review 5.  Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs).

Authors:  Trevor Riley; David Christopher; Jan Arp; Andrea Casazza; Agnes Colombani; Andrew Cooper; Monisha Dey; Janet Maas; Jolyon Mitchell; Maria Reiners; Nastaran Sigari; Terrence Tougas; Svetlana Lyapustina
Journal:  AAPS PharmSciTech       Date:  2012-07-14       Impact factor: 3.246

6.  Dissolution testing of powders for inhalation: influence of particle deposition and modeling of dissolution profiles.

Authors:  Sabine May; Birte Jensen; Claudius Weiler; Markus Wolkenhauer; Marc Schneider; Claus-Michael Lehr
Journal:  Pharm Res       Date:  2014-05-23       Impact factor: 4.200

7.  Using pH abnormalities in diseased skin to trigger and target topical therapy.

Authors:  Khalida Rizi; Rebecca J Green; Michael X Donaldson; Adrian C Williams
Journal:  Pharm Res       Date:  2011-05-26       Impact factor: 4.200

8.  Epithelial profiling of antibiotic controlled release respiratory formulations.

Authors:  Hui Xin Ong; Daniela Traini; Mary Bebawy; Paul Michael Young
Journal:  Pharm Res       Date:  2011-05-26       Impact factor: 4.200

9.  Modification of disodium cromoglycate passage across lung epithelium in vitro via incorporation into polymeric microparticles.

Authors:  Mehra Haghi; Rania Salama; Daniela Traini; Mary Bebawy; Paul M Young
Journal:  AAPS J       Date:  2011-12-28       Impact factor: 4.009

10.  Temozolomide-based dry powder formulations for lung tumor-related inhalation treatment.

Authors:  Nathalie Wauthoz; Philippe Deleuze; Amandine Saumet; Christophe Duret; Robert Kiss; Karim Amighi
Journal:  Pharm Res       Date:  2010-11-30       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.